We've found
2,489
archived clinical trials in
Endometrial Cancer
We've found
2,489
archived clinical trials in
Endometrial Cancer
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Updated: 7/7/2015
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated: 7/7/2015
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Updated: 7/7/2015
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated: 7/7/2015
Click here to add this to my saved trials
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Updated: 7/25/2015
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated: 7/25/2015
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Updated: 7/25/2015
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated: 7/25/2015
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
Updated: 8/3/2015
Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Updated: 9/10/2015
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Updated: 9/10/2015
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Click here to add this to my saved trials
Disseminated Endometrial Cancer Cells During Sonohysterography
Updated: 9/30/2015
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated: 9/30/2015
Disseminated Endometrial Cancer Cells During Sonohysterography
Updated: 9/30/2015
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated: 9/30/2015
Click here to add this to my saved trials
Sexual Functioning in Endometrial Cancer
Updated: 9/30/2015
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated: 9/30/2015
Sexual Functioning in Endometrial Cancer
Updated: 9/30/2015
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated: 9/30/2015
Click here to add this to my saved trials
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Updated: 10/1/2015
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated: 10/1/2015
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Updated: 10/1/2015
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Updated: 10/1/2015
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Click here to add this to my saved trials
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery
Updated: 11/11/2015
A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment
Status: Enrolling
Updated: 11/11/2015
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Updated: 12/15/2015
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Updated: 12/15/2015
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Updated: 12/15/2015
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Updated: 12/15/2015
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Status: Enrolling
Updated: 12/15/2015
Click here to add this to my saved trials
RAD001 in Recurrent Endometrial Cancer Patients
Updated: 1/6/2016
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated: 1/6/2016
RAD001 in Recurrent Endometrial Cancer Patients
Updated: 1/6/2016
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated: 1/6/2016
Click here to add this to my saved trials
Lymph Node Counts in Endometrial Cancer Staging
Updated: 1/20/2016
A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging
Status: Enrolling
Updated: 1/20/2016
Lymph Node Counts in Endometrial Cancer Staging
Updated: 1/20/2016
A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging
Status: Enrolling
Updated: 1/20/2016
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Click here to add this to my saved trials
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Updated: 2/3/2016
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: Enrolling
Updated: 2/3/2016
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Updated: 3/10/2016
Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin
Status: Enrolling
Updated: 3/10/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Updated: 3/31/2016
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status: Enrolling
Updated: 3/31/2016
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Updated: 4/7/2016
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Click here to add this to my saved trials